Your browser doesn't support javascript.
loading
Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients
Ceniceros, L; Aristu, J; Castañón, E; Rolfo, C; Legaspi, J; Olarte, A; Valtueña, G; Moreno, M; Gil-Bazo, I.
Affiliation
  • Ceniceros, L; Clínica Universidad de Navarra. Department of Oncology. Pamplona. Spain
  • Aristu, J; Clínica Universidad de Navarra. Department of Radiation Oncology. Pamplona. Spain
  • Castañón, E; Clínica Universidad de Navarra. Department of Oncology. Pamplona. Spain
  • Rolfo, C; Antwerp University Hospital. Oncology Department and Multidisciplinary Oncology Center Antwerp (MOCA). Edegem. Belgium
  • Legaspi, J; Clínica Universidad de Navarra. Department of Oncology. Pamplona. Spain
  • Olarte, A; Clínica Universidad de Navarra. Department of Radiation Oncology. Pamplona. Spain
  • Valtueña, G; Clínica Universidad de Navarra. Department of Radiation Oncology. Pamplona. Spain
  • Moreno, M; Clínica Universidad de Navarra. Department of Radiation Oncology. Pamplona. Spain
  • Gil-Bazo, I; Clínica Universidad de Navarra. Department of Oncology. Pamplona. Spain
Clin. transl. oncol. (Print) ; 18(3): 259-268, mar. 2016. tab, ilus
Article de En | IBECS | ID: ibc-148709
Bibliothèque responsable: ES1.1
Localisation: BNCS
ABSTRACT
Introduction: Lung cancer is the most frequent neoplasm in humans. Surgery is considered the best therapeutic approach for stage I non-small lung cell cancer (NSCLC). However, a remarkable amount of patients are considered as inoperable. Stereotactic body radiotherapy (SBRT) has risen as an option for those patients, rendering excellent results in quality of life and survival. Materials and methods: We analyzed clinical studies published between 2002 and 2015 which included SBRT as a treatment modality. Our own clinical series was analyzed as well. The patterns of failure following SBRT were investigated, together with the outcomes and the toxicity observed. Results: SBRT has proven to maintain an excellent local control. The analysis showed the tumor size and the histology as determinant factors for the response to treatment. Conclusion: According to the published evidence as well as our own experience, SBRT is a safe and feasible approach for early NSCLC. Its results may be comparable with surgery treatment (AU)
RESUMEN
No disponible
Sujet(s)
Recherche sur Google
Collection: 06-national / ES Base de données: IBECS Sujet principal: Pneumopathie infectieuse / Radiothérapie / Bases de données bibliographiques / Carcinome pulmonaire non à petites cellules / Diabète / Oesophagite / Défaillance cardiaque / Tumeurs du poumon Type d'étude: Diagnostic_studies Aspects: Patient_preference Limites: Female / Humans / Male Langue: En Journal: Clin. transl. oncol. (Print) Année: 2016 Type de document: Article
Recherche sur Google
Collection: 06-national / ES Base de données: IBECS Sujet principal: Pneumopathie infectieuse / Radiothérapie / Bases de données bibliographiques / Carcinome pulmonaire non à petites cellules / Diabète / Oesophagite / Défaillance cardiaque / Tumeurs du poumon Type d'étude: Diagnostic_studies Aspects: Patient_preference Limites: Female / Humans / Male Langue: En Journal: Clin. transl. oncol. (Print) Année: 2016 Type de document: Article